BRCA2 and digestive system neoplasm: As we previously mentioned, TP53 mutations were almost equally distributed in both BRCA2 wild-type and mutant gastrointestinal tumors, and it would be of value to examine the genetic mutations of the TP53 gene before applying MMC to patients with BRCA2 monoallelic and biallelic mutant tumors.